Screener
Kymera Therapeutics KYMR CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other assets and liabilities | (4) | (106) |
| Net cash used in operating activities | $(142,905) | $(139,034) |
| Investing activities | ||
| Purchase of property and equipment, net | (907) | (1,162) |
| Purchases of investments | (390,921) | (141,907) |
| Maturities of investments | 269,033 | 251,705 |
| Net cash (used in) provided by investing activities | $(122,795) | $108,636 |
| Financing activities |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's capex?
- Kymera Therapeutics (KYMR) reported capex of $473K in Q2 2026.
- How has Kymera Therapeutics's capex changed year-over-year?
- Kymera Therapeutics's capex decreased by 31.9% year-over-year, from $695K to $473K.
- What is the long-term trend for Kymera Therapeutics's capex?
- Over 4 years (2021 to 2025), Kymera Therapeutics's capex has grown at a -2.4% compound annual growth rate (CAGR), from $1.6M to $1.45M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Kymera Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude